APTO News and Press, Aptose Biosciences Inc. From 03/23/23

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continu...

2023-03-22 17:35:12 ET Major earnings expected after the bell on Thursday include: Ideanomics ( IDEX ) Planet 13 Holdings ( OTCQX:PLNHF ) Spruce Power Holding Corporation ( SPRU ) Heron Therapeutics ( HRTX ) ADMA Biologics ( ADMA ) For further...

2023-03-13 04:02:42 ET In wake of the bank's collapse with turmoil surrounding Silicon Valley Bank, several smaller pharma, biotech companies and health care equipment have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). Among the biotec...

SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies...

SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter a...

SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com It’s time to start the week with a breakdown of the biggest pre-market stock movers to keep a watch on Monday! Moving stocks this morning are clinical trial results, a bankru...

• AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial • New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient • Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile ...

SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, ...

Aptose Biosciences ( NASDAQ: APTO ) said on Monday it had entered into an equity distribution agreement of up to $50M with JonesTrading Institutional Services as agent. Under the terms of the equity distribution agreement, the company can issue and sell through the agent, common s...